Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B52ae56d2544165b994b7e11a62782c26> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B52ae56d2544165b994b7e11a62782c26 NCIT_P378 "NCI" @default.
- B52ae56d2544165b994b7e11a62782c26 type Axiom @default.
- B52ae56d2544165b994b7e11a62782c26 annotatedProperty IAO_0000115 @default.
- B52ae56d2544165b994b7e11a62782c26 annotatedSource NCIT_C132295 @default.
- B52ae56d2544165b994b7e11a62782c26 annotatedTarget "An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers." @default.